Leo I. Gordon
About
Leo I. Gordon is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics.
According to data from OpenAlex, Leo I. Gordon has authored 453 papers receiving a total of 15.0k indexed citations (citations by other indexed papers that have themselves been cited), including 247 papers in Pathology and Forensic Medicine, 210 papers in Oncology and 105 papers in Genetics. Recurrent topics in Leo I. Gordon's work include Lymphoma Diagnosis and Treatment (242 papers), Chronic Lymphocytic Leukemia Research (95 papers) and Viral-associated cancers and disorders (68 papers). Leo I. Gordon is often cited by papers focused on Lymphoma Diagnosis and Treatment (242 papers), Chronic Lymphocytic Leukemia Research (95 papers) and Viral-associated cancers and disorders (68 papers). Leo I. Gordon collaborates with scholars based in United States, Canada and Philippines. Leo I. Gordon's co-authors include Thomas E. Witzig, Andrew M. Evens, Christos Emmanouilides, Jane N. Winter, Gregory A. Wiseman, Christine A. White, Myron S. Czuczman, Nancy L. Bartlett, Pratik S. Multani and Mansoor N. Saleh and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.
In The Last Decade
Leo I. Gordon
431 papers receiving 14.6k citations
Hit Papers
Peers
Leo I. Gordon
Andrew D. Zelenetz United States
Andreas Engert Germany
Steven T. Rosen United States
Wyndham H. Wilson United States
Michael Pfreundschuh Germany
Anas Younes United States
Richard Greil Austria
Christer Sundström Sweden
Michael Hummel Germany
Alexandar Tzankov Switzerland
Citations per year, relative to Leo I. Gordon Leo I. Gordon (= 1×)
peers
Andrew D. Zelenetz
Countries citing papers authored by Leo I. Gordon
Since
Specialization
Citations
This map shows the geographic impact of Leo I. Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leo I. Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leo I. Gordon more than expected).
Fields of papers citing papers by Leo I. Gordon
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Leo I. Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leo I. Gordon. The network helps show where Leo I. Gordon may publish in the future.
Co-authorship network of co-authors of Leo I. Gordon
This figure shows the co-authorship network connecting the top 25 collaborators of Leo I. Gordon. A scholar is included among the top collaborators of Leo I. Gordon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leo I. Gordon. Leo I. Gordon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mahmood, Bushra, Leo I. Gordon, James Wilton, et al.. (2025). Impact of the COVID-19 Pandemic and Control Measures on Screening and Diagnoses of Type 2 Diabetes in British Columbia. International Journal of Environmental Research and Public Health. 22(4). 519–519.
2.
Valcárcel, Bryan, Kerry J. Savage, Brian K. Link, et al.. (2024). Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research Agenda. JCO Oncology Practice. 21(6). 801–812.
3.
Lin, Adam Yuh, et al.. (2022). Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma. SHILAP Revista de lepidopterología.
4.
Lin, Adam Yuh, Bongseo Choi, Taehoon Sim, et al.. (2022). Enhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide–coated nanoparticles. Blood Advances. 6(15). 4581–4592.
5.
Lesovaya, Ekaterina A., О. В. Морозова, К. I. Kirsanov, et al.. (2020). A Novel Approach to Safer Glucocorticoid Receptor–Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition. Molecular Cancer Therapeutics. 19(9). 1898–1908.
6.
Rink, Jonathan S., Adam Yuh Lin, Kaylin M. McMahon, et al.. (2020). Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis. Journal of Biological Chemistry. 296. 100100–100100.
7.
Lin, Adam Yuh, Michael J. Cuttica, Michael G. Ison, & Leo I. Gordon. (2020). Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID‐19 infection: Case report and literature review. SHILAP Revista de lepidopterología. 1(2). 596–600.
8.
Ramchandren, Radhakrishnan, Ranjana H. Advani, Stephen M. Ansell, et al.. (2019). Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research. 25(6). 1718–1726.
9.
Frank, Matthew J., Patrick M. Reagan, Nancy L. Bartlett, et al.. (2018). In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. Cancer Discovery. 8(10). 1258–1269.
10.
Evens, Andrew M., Ranjana H. Advani, Irene Helenowski, et al.. (2018). Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. Journal of Clinical Oncology. 36(30). 3015–3022.
11.
Maloney, David G., Jeremy S. Abramson, Maria Lia Palomba, et al.. (2017). Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration. Blood. 130. 1552–1552.
12.
Evens, Andrew M., Sriram Balasubramanian, Julie M. Vose, et al.. (2015). A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. Clinical Cancer Research. 22(5). 1059–1066.
13.
Solal‐Céligny, Philippe, Monica Bellei, Luigi Marcheselli, et al.. (2012). Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. Journal of Clinical Oncology. 30(31). 3848–3853.
14.
Smith, Mitchell R., Hailun Li, Leo I. Gordon, et al.. (2012). Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. Journal of Clinical Oncology. 30(25). 3119–3126.
15.
Gordon, Leo I., Fangxin Hong, Richard I. Fisher, et al.. (2012). Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). Journal of Clinical Oncology. 31(6). 684–691.
16.
Witzig, Thomas E., Paul A. S. Fishkin, Leo I. Gordon, et al.. (2011). Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leukemia & lymphoma. 52(7). 1188–1199.
17.
Evens, Andrew M., William G. Spies, Irene Helenowski, et al.. (2009). The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial. Clinical Cancer Research. 15(20). 6462–6471.
18.
Bhalla, Savita, Sriram Balasubramanian, Kevin A. David, et al.. (2009). PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells. Clinical Cancer Research. 15(10). 3354–3365.
19.
Czuczman, Myron S., Christos Emmanouilides, Mohamed Darif, et al.. (2007). Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy. Journal of Clinical Oncology. 25(27). 4285–4292.
20.
Gordon, Leo I., et al.. (2001). Value of vertebral X-rays in osteoporosis.. PubMed. 97(3). 102–5.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Andrew D. Zelenetz Breakdown of academic impact, for papers by Andreas Engert Breakdown of academic impact, for papers by Steven T. Rosen Breakdown of academic impact, for papers by Wyndham H. Wilson Breakdown of academic impact, for papers by Michael Pfreundschuh Breakdown of academic impact, for papers by Anas Younes Breakdown of academic impact, for papers by Richard Greil Breakdown of academic impact, for papers by Christer Sundström Breakdown of academic impact, for papers by Michael Hummel Breakdown of academic impact, for papers by Alexandar Tzankov